<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03787667</url>
  </required_header>
  <id_info>
    <org_study_id>ColoRadiomics</org_study_id>
    <nct_id>NCT03787667</nct_id>
  </id_info>
  <brief_title>Application of Radiomics in Precise Preoperative Diagnosis and Prognsis Evaluation of Colorectal Cancer.</brief_title>
  <official_title>Application of Radiomics in Precise Preoperative Diagnosis and Prognsis Evaluation of Colorectal Cancer: a Prospective, Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, clinical study. This study is to collect and analyze data of radiomics
      of primary site or metastasis of colorectal cancer aiming to precisizing preoperative
      diagnosis and long-term prognsis evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>2 years</time_frame>
    <description>The sensitivity of radiomics in predicting regional or distant synchronous colorectal metastasis</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Colorectal Cancer Stage I-IV</condition>
  <arm_group>
    <arm_group_label>Patients with pathologically diagnosed colorectal cancer</arm_group_label>
    <description>Patients with pathologically diagnosed colorectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT or MRI based Radiomics</intervention_name>
    <description>Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.</description>
    <arm_group_label>Patients with pathologically diagnosed colorectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients received enhaced CT or MRI test must have baseline evaluations performed prior to
        the study and must meet all inclusion and exclusion criteria. In addition, the patient must
        be thoroughly informed about all aspects of the study, including the study visit schedule
        and required evaluations and all regulatory requirements for informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathologically confirmed colorectal cancer

          -  Male or female aged 18-75 years old on the day of signing informed consent.

          -  Patients who received imageological examination of primary or metastasis

          -  Patients who received surgical resection of primary or metastasis

          -  Patients must have a performance status of â‰¤1 on the ECOG Performance Scale.

          -  Colorectal cancer is the only malignant tumor

          -  Written informed consent must be obtained from patient or patient's legal
             representative and ability for patient to comply with the requirements of the study

        Exclusion Criteria:

          -  Patients received adjuvant treatment prior to imageological examination

          -  Tis stage patients

          -  Paitents who diagnosed with malignant disease within 5 years.

          -  Patients with a history or current evidence of any condition or abnormality that might
             confound the results of the study, interfere with the patient's participation for the
             full duration of the study, or is not in the best interest of the patient to
             participate, in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guoxiang Cai, M.D.Ph.D.</last_name>
    <phone>+86 13611831623</phone>
    <email>gxcai@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoxiang Cai</last_name>
      <phone>+8613611831623</phone>
      <phone_ext>+8613611831623</phone_ext>
      <email>gxcai@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 22, 2018</study_first_submitted>
  <study_first_submitted_qc>December 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2018</study_first_posted>
  <last_update_submitted>December 22, 2018</last_update_submitted>
  <last_update_submitted_qc>December 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Guoxiang Cai</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

